이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Pre-workout Supplement, Arrhythmias and Exercise Stress Test

2026년 10월 1일 업데이트: Pedro Gabriel Senger Braga, University of Sao Paulo

Can a Pre-workout Supplement Cause Arrhythmias During Physical Exercise in Young Physically Active Individuals? A Randomized, Double-blind, Placebo-controlled Study

Pre-workout supplements are widely used by physically active individuals to enhance exercise performance. These products typically contain stimulant substances such as caffeine, beta-alanine, arginine, and tyrosine, which act on the cardiovascular and central nervous systems. Although their ergogenic effects are well established, their safety profile - particularly regarding cardiac arrhythmias during exercise - has not been thoroughly investigated.

This study aimed to evaluate whether the acute ingestion of a commercially available multi-ingredient pre-workout supplement (V-FORT® ULTRA, Vitafor, Brazil) could trigger cardiac arrhythmias during a treadmill exercise stress test in young, physically active adults. A randomized, double-blind, placebo-controlled crossover design was used. Participants underwent two exercise stress tests separated by 3 to 10 days: a familiarization test (Day 1) and an intervention test (Day 2), in which they received either the pre-workout supplement or a placebo beverage. Neither the participants nor the research team conducting the test were aware of the allocated intervention until after test completion.

연구 개요

상세 설명

Participants were recruited via social media and screened for eligibility using the International Physical Activity Questionnaire (IPAQ). Only individuals meeting the criteria for physical activity (≥150 minutes/week of moderate-intensity or ≥75 minutes/week of vigorous-intensity exercise) and with prior experience using pre-workout supplements were enrolled.

On Day 1, all participants underwent a familiarization treadmill exercise stress test. Those presenting cardiac arrhythmias at baseline were excluded from the study.

On Day 2 (3 to 10 days later), participants were randomized in a 1:1 ratio to receive either the active supplement (V-FORT® ULTRA: 200 mg caffeine, 2,000 mg beta-alanine, 1,000 mg arginine, 600 mg tyrosine, 300 mg phenylalanine, 415 mg carnitine, vitamins and minerals; 8 kcal per 8 g sachet) or a placebo (Tang® powdered juice: carbohydrates, sodium, vitamin C, and vitamin D; no stimulant substances). The beverage was prepared by the study coordinator in a separate room and consumed by the participant up to 3 hours before the exercise stress test. Both tests were performed at the same time of day for each participant.

The primary outcome was the occurrence of cardiac arrhythmias during the exercise stress test and the 6-minute post-exercise recovery phase, assessed by continuous 12-lead ECG. Secondary outcomes included adverse effects (tachycardia, paraesthesia) and exercise stress test duration.

Statistical analysis included descriptive statistics, normality testing (Shapiro-Wilk), paired comparisons (paired t-test or Wilcoxon signed-rank test for continuous variables; McNemar test for categorical variables), and logistic regression for confounder adjustment. IBM SPSS software was used for all analyses.

연구 유형

중재적

등록 (실제)

62

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • São Paulo
      • São Paulo, São Paulo, 브라질, 05021-010
        • Pro-Coracao

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

Age 18 to 30 years Both sexes Physically active, defined as engaging in at least 150 minutes of moderate-intensity physical activity or 75 minutes of vigorous-intensity physical activity per week, assessed by the International Physical Activity Questionnaire (IPAQ) Prior experience with pre-workout supplements (at least one previous use of any stimulant-based pre-workout supplement) No cardiac arrhythmias identified during the familiarization exercise stress test (Day 1)

Exclusion Criteria:

Presence of cardiac arrhythmias identified during the familiarization exercise stress test (Day 1) Physical inactivity (below the minimum physical activity thresholds on IPAQ) No prior use of any pre-workout or stimulant supplement Use of medications that may interfere with cardiovascular responses to exercise or supplementation Presence of known cardiovascular, metabolic, or musculoskeletal conditions that contraindicate exercise testing Orthopaedic limitations precluding treadmill exercise

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Pre-Workout Supplement

Participants received a single dose of V-FORT® ULTRA (Vitafor, Brazil), a multi-ingredient pre-workout supplement containing 200 mg caffeine, 2,000 mg beta-alanine, 1,000 mg arginine, 600 mg tyrosine, 300 mg phenylalanine, 415 mg carnitine, 1.9 g carbohydrate, vitamins (C, E, B6, B12) and minerals (sodium, magnesium, zinc); 8 kcal per 8 g sachet. The beverage was consumed up to 3 hours before the treadmill exercise stress test.

Single dose of containing 200 mg caffeine, 2,000 mg beta-alanine, 1,000 mg arginine, 600 mg tyrosine, 300 mg phenylalanine, 415 mg carnitine, 1.9 g carbohydrate, vitamins (C, E, B6, B12) and minerals (sodium, magnesium, zinc); 8 kcal per 8 g sachet. Consumed up to 3 hours before the treadmill exercise stress test.

위약 비교기: Placebo

Participants received a single dose of Tang® powdered juice (placebo), containing 2.6 g carbohydrate, 2.4 g sugars, 22 mg sodium, 1.1 mg zinc, 23 mg vitamin C, and 2.5 mcg vitamin D, with no stimulant substances. The beverage was prepared to be visually and organoleptically indistinguishable from the active supplement and was consumed up to 3 hours before the treadmill exercise stress test.

Juice

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Occurrence of Cardiac Arrhythmias During the Exercise Stress Test
기간: During the treadmill exercise stress test and throughout the 6-minute post-exercise recovery phase (approximately 30 to 60 minutes per session, on Day 2)

Presence or absence of cardiac arrhythmias identified on continuous 12-lead ECG during the treadmill exercise stress test and the 6-minute post-exercise recovery phase, compared between the pre-workout supplement and placebo conditions.

During the treadmill exercise stress test and throughout the 6-minute post-exercise recovery phase (approximately 30 to 60 minutes per session, on Day 2)

2차 결과 측정

결과 측정
측정값 설명
기간
Haemodynamic Responses During the Exercise Stress Test
기간: At rest, during each stage of the treadmill exercise stress test, at peak effort, and during the 6-minute post-exercise recovery phase on Day 2

Blood pressure (systolic and diastolic) and heart rate measured at rest, at the end of each exercise stage, at peak effort, and during the post-exercise recovery phase (minutes 1, 2, 4, and 6), compared between the pre-workout supplement and placebo conditions.

At rest, during each stage of the treadmill exercise stress test, at peak effort, and during the 6-minute post-exercise recovery phase on Day 2
Exercise Stress Test Duration
기간: Day 1 (familiarization test) and Day 2 (intervention test), separated by 3 to 10 days

Total duration of the treadmill exercise stress test in minutes, compared between the pre-workout supplement and placebo conditions (Day 2), and between the familiarization test (Day 1) and the intervention test (Day 2) within the same participant.

Day 1 (familiarization test) and Day 2 (intervention test), separated by 3 to 10 days

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 3일

기본 완료 (실제)

2026년 9월 3일

연구 완료 (실제)

2026년 9월 3일

연구 등록 날짜

최초 제출

2026년 9월 27일

QC 기준을 충족하는 최초 제출

2026년 9월 27일

처음 게시됨 (실제)

2026년 10월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 1일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 8.071.338
  • 92811525.4.0000.0068 (기타 식별자: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다